Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24) is an NIH funding opportunity from the Office of Research Infrastructure Programs (ORIP) that supports development of animal models, cell lines, and related research resources for studying human health conditions and diseases. Clinical trials are not allowed under this announcement.

Eligible applicants include nonprofits, universities, state and local governments, and private sector organizations. The co-funding mechanism includes the INCLUDE Project for Down syndrome research. Applications are due May 27, 2026.

RFA-OD-25-010: Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed) Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs ( ORIP ) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers.

The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE ( INCLUDE Project ) Funding Opportunity Title Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed) R24 Resource-Related Research Projects Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON) Companion Funding Opportunity See Section III. 3. Additional Information on Eligibility .

Assistance Listing Number(s) Funding Opportunity Purpose The Office of Research Infrastructure Programs ( ORIP ) encourages grant applications aimed at developing, characterizing, or improving research models of human health and diseases; developing biology based new approach methodologies (NAMs) applicable to human health and diseases; or improving access to information about or generated from the use of models of human disease.

The models, including NAMs, and related biological materials developed must be broadly applicable to the scientific interests of two or more NIH Institutes or Centers (ICs) and must evaluate diseases and processes that impact multiple organ systems in order to align with the ORIP’s NIH-wide mission and programs.

Applications must describe the need for and the potential impact of the proposed resources on the research community across a range of scientific disciplines supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research or that do not have a broad impact on the NIH-wide research community will not be accepted.

Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other ICs will also not be accepted, if submitted in response to this notice of funding opportunity (NOFO).

Funding Opportunity Goal(s) The Office of Research Infrastructure Programs (ORIP) is a program office in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) dedicated to supporting research infrastructure and related research resource programs. ORIP consists of the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI).

Open Date (Earliest Submission Date) Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide , follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants. gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

Use the NIH ASSIST system to prepare, submit and track your application online. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants. gov and eRA Commons to track your application.

Check with your institutional officials regarding availability. Use Grants. gov Workspace to prepare and submit your application and eRA Commons to track your application.

Part 1. Overview Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.

Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII.

Agency Contacts Section VIII. Other Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description Experimental research models are indispensable for studying the genetic basis and pathobiological mechanisms underlying human diseases, identifying drug targets, and developing effective preventive and therapeutic approaches.

Human health and disease-related resources include biology-based new approach methodologies (NAMs); naturally occurring mutant and genetically modified animals; related biological materials, such as nucleic acids, proteins, cell cultures, and tissues; reagents; and knowledge of an animal’s genome, life cycle, molecular, cellular and physiological phenotypes, and behaviors.

Resources can also include information needed for optimal use of animal models, such as physical and genetic maps or computer models. ORIP supports development, maintenance, and distribution of these various types of resources related to models of human disease encompassing animals, small model organisms, and in particular NAMs that are reflective of human biology and pathophysiology.

ORIP’s intent with this NOFO is to support resource-related research projects that are aimed at developing and characterizing new human health- and disease-based resources, improving existing resources, or acquiring deep understanding of a model system to improve the utilization, accessibility, and translational value of experimental research models to the research community.

The NIH-wide mission of ORIP is to support all NIH ICs that fund basic, preclinical, and translational research by strengthening their existing programs, developing research resources, advancing areas of emerging science, and developing new initiatives to move biomedical research forward.

Therefore, proposed studies, models, technologies, methodologies, and biological materials must be applicable to two or more NIH ICs and must explore multiple organ systems or evaluate diseases and processes that impact multiple organ systems.

An application under this NOFO may be predominantly research based if that research potentially leads to the development of tools or resources that will have a broad impact on the NIH-wide biomedical research community. An application also may be aimed at final development or enhancement of existing resources.

Applications responding to this NOFO should: Demonstrate the need for the proposed resources or technologies/tools within broad biomedical research communities and the relevance of the resources and technologies/tools to a range of scientific disciplines.

Address the impact, benefit, utilization, distribution, and accessibility of the proposed resources and technologies/tools to broad biomedical research areas supported by multiple NIH ICs. Describe plans to track potential impact of the proposed resources and technologies/tools.

Describe potential sources of support for the resources and technologies/tools as well as plans to ensure the continued availability of the resources and technologies/tools to the research community after the ORIP-supported grant ends, such as plans to deposit the resources to stock centers or databases accessible to the research community.

Include a replication and validation plan for proposed models or related resources to be developed. Cost recovery is not required for applications responding to this NOFO. Proposed studies, models, technologies, methodologies, and biological materials that relate strictly to a specific disease or research discipline or are relevant to the mission and programs of a single NIH IC will not be considered suitable for this NOFO.

Such applications should be directed to the IC with a specific interest in that mission. For example, investigators interested in developing resources with a primary focus on aging, cancer, cardiovascular disease, infectious disease, or neurological disorders should contact respective NIH ICs relevant to these topics.

Furthermore, applications proposing studies to develop a limited number of resources or are related primarily to the interest of one NIH IC and only peripherally to the interests of other ICs are not acceptable. Proposed projects under this NOFO should be aimed at generating a substantial amount of human health and disease model related resources and information with broad impacts.

Examples of resource-related projects suitable for this NOFO, include, but are not limited to: Development of new approach methodologies (NAMs), including laboratory ( in vitro or in chemico) , computer-based ( in silico) , or hybrid methods—advancing our ability to simulate physiological and disease processes.

These tools aim to model the complex interactions among molecules, cells, tissues, and organs outside of the whole organism, and serve as valuable complements to animal research. Rigorous testing and validation of these models to demonstrate reliability, reproducibility, and human biological relevance is essential.

Development of informatics tools or systems biology approaches, especially artificial intelligence or machine learning tools, that integrate various types of data, including genomic, proteomic, metabolomic, imaging, or phenotypic data, to generate novel hypotheses and improve the value of human health and disease models for biomedical research.

Development, improvements or refinements of technologies or methods applicable to human health and disease model research that aim to enhance its rigor and reproducibility. Generation of mutant or transgenic animal models for studying fundamental biological processes and investigating mechanisms underlying a broad range of human diseases that impact multiple organ systems.

Production of antibodies or other reagents and demonstration of their utility for quantifying or characterizing macromolecules or cells in animal models of a variety of human diseases. Development of information resources for generating novel hypotheses and improving the utilization of animals in biomedical research, including deep phenotyping of organelles, single cells, cellular networks, microbiomes, or behaviors.

Development of genetic, genomic, proteomic, metabolomic or phenomic tools for deep characterization and understanding of disease-related biological processes. Generation of genetic resources at the genome scale, including DNA or viral vector libraries, for gene editing of cell lines, germplasm, or somatic cells.

Development of methods or tools for improving cryopreservation, or other long-term preservation approaches, of animal cells, germplasm, embryos, or genetic stocks. Development of methods or tools for characterizing stem cells and advancing techniques of regenerative medicine.

These include stem cell generation, reprogramming, characterization, and transplantation; stem cell-based therapeutic applications; and analysis of the safety of newer technologies such as RNA-guided endonucleases (CRISPR/Cas9), optogenetics/chemogenetics, and humanized animal models generated with non-fetal human tissues.

Generation of models or resources that can contribute to the understanding of newly emerging human pathogens of interest to multiple NIH ICs and may be applied in response to pandemics and other active NIH-wide public health initiatives.

Applications for developing a limited number of resources are not suitable for this NOFO and may be appropriate for research project grant activities through R21 or R01 awards supported by ORIP or NIH ICs.

Examples of projects that WILL NOT be supported under this NOFO include those that: Develop experimental models, cell lines, or NAMs that relate strictly to a specific disease or research area or are primarily relevant to the mission and programs of predominantly one NIH IC.

Develop cell lines of a single cell type that relate strictly to a specific disease or research area, or that are primarily relevant to the mission and programs of predominantly one NIH IC. Primarily focus on husbandry and management of animal colonies. Primarily focus on genomic sequencing of model organisms (e.g., only for data deposition into a repository).

Primarily focus on creating, expanding, or maintaining genomic or other types of databases. Create or maintain individual model organism databases. Develop or distribute wild-type animals and related biospecimens treated with diet, drug, toxin, infectious agents, or other environmental factors.

Develop or distribute wild-type animals and related biospecimens subjected to physical or surgical manipulations. Involve threatened or endangered species. Develop, expand, or maintain repositories of specific tissues and related bio-specimens (i.e. RNA extracts, processed tissues) from model organisms.

Primarily involve human subjects, human cell lines, or related human biological materials. This NOFO will support the development of human health and disease models and related resources to advance a variety of important research areas and have an impact on the NIH-wide biomedical research community.

Those applications proposing to develop resources should describe plans to deposit their resources to stock centers or databases accessible to the research community and register their resources with current resource tagging and identification initiatives, such as FORCE 11 . These projects should also encourage investigators who use the resources to make use of the Research Resource Identifiers (RRIDs) in their publications and reports.

Program Directors/Principal Investigators (PD/PIs) planning to work with their institutions to submit applications to this NOFO are strongly encouraged to contact the scientific contacts prior to submission (see Scientific/Research Contacts in Section VII.

Agency Contacts) to receive guidance on appropriateness of the intended resource and research plans for this program, competitiveness of a potential application, and alignment with ORIP's program priorities. See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. Application Types Allowed The OER Glossary and the How to Apply - Application Guide provide details on these application types.

Only those application types listed here are allowed for this NOFO. Not Allowed: Only accepting applications that do not propose clinical trials. Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards Contingent upon NIH appropriations and the submission of meritorious applications, NIH intends to commit $5,000,000 per fiscal year in FY 2026-2029 to fund at least six awards per fiscal year, including Down Syndrome related awards if there are any. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) should refer to NOT-OD-23-075 and must contact a Scientific/ Research Contact for approval at least 6 weeks before submitting the new or renewal application. For Renewal (a. k.

a. Type 2) applications including Renewal Resubmission applications, no more than a 5 percent increase of direct cost based on a previous non-competing year with the highest direct cost in the prior four-year funding cycle will be accepted. The duration of the proposed project may not exceed four years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. Section III.

Eligibility Information Higher Education Institutions - Includes all types Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Foreign Organizations/Foreign Collaborations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are not allowed. Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award.

All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually .

The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.

Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

Grants. gov – Applicants must have an active SAM registration in order to complete the Grants. gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role.

Obtaining an eRA Commons account can take up to 2 weeks. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide . This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1. 2 Definition of Terms.

3. Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.

3. 7. 4 Submission of Resubmission Application .

This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3. 9.

4 Similar, Essentially Identical, or Identical Applications ). Section IV. Application and Submission Information 1.

Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.

gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice , or other notice from NIH Guide for Grants and Contracts ).

Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review. All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO. All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Other Project Information All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed. All instructions in the How to Apply - Application Guide must be followed.

All instructions in the How to Apply - Application Guide must be followed. PHS 398 Cover Page Supplement All instructions in the How to Apply - Application Guide must be followed.

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Resource Sharing Plan : Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide .

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan.

All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide .

No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide , with the following additional instructions: If you answered “Yes” to the question “Are Human Subjects Involved?

” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record. Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed.

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed. PHS Assignment Request Form All instructions in the How to Apply - Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.

1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants. gov 4. Submission Dates and Times Part I.

contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants. gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons , NIH’s electronic system for grants administration.

NIH and Grants. gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.

gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications .

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission. Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide . 5.

Intergovernmental Review (E. O. 12372) This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement . Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7. 9.

1 Selected Items of Cost . 7. Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide .

Paper applications will not be accepted. Applicants must complete all required registrations before the application due date. Section III.

Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance.

For assistance with application submission, contact the Application Submission Contacts in Section VII. All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form . Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

See Section III of this NOFO for information on registration requirements. The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide .

See more tips for avoiding common errors. Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200. 113 and NIH Grants Policy Statement Section 4.

1. 35 . Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.

hhs. gov . Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy Section V.

Application Review Information Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Does the proposed [Center] address the needs of the research [programs/projects/network/consortium/resource] that it will [coordinate/administer/serve]? Is the scope of activities proposed for the [Center] appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the research [program/projects/network/consortium/resource]?

Are the PD(s)/PI(s) and other personnel well suited to their roles in the [Center]? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing [adjective] research? Do the investigators demonstrate significant experience with coordinating collaborative [basic or clinical] research?

If the Center is multi-PD/PI, do the investigators have complementary and integrated expertise and skills; are their [leadership approach, governance, plans for conflict resolution, and organizational structure] appropriate for the [Center]? Does the applicant have experience overseeing selection and management of subawards, if needed?

Does the application propose novel [organizational concepts, management strategies, or instrumentation] in coordinating the research [program/projects/network/consortium/resource] the [Center] will serve? Are the concepts, strategies, or instrumentation novel to one type of research program or applicable in a broad sense?

Is a refinement, improvement, or new application of [organizational concepts, management strategies or instrumentation] proposed? Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the research [program/projects/network/consortium/ resource] the [Center] will serve?

Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the [program/projects/network/consortium/resource], as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented?

If the [program/projects/network/consortium/ resource] is in the early stages of operation, does the proposed strategy adequately establish feasibility and manage the risks associated with the activities of the [program/projects/network/consortium/resource]? Are an appropriate plan for work-flow and a well-established timeline proposed?

Have the investigators presented adequate plans to ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects? Will the institutional environment in which the [Center] will operate contribute to the probability of success in facilitating the research [program/projects/network/consortium] it serves?

Are the institutional support, equipment and other physical resources available to the investigators adequate for the [Center] proposed? Will the [Center] benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?

Additional Review Criteria As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these